• 1. Excitation energies from ground-state density-functionals by means of generator coordinates
  A. B. F. da Silva,K. Capelle Phys. Chem. Chem. Phys., 2009,11, 4564-4569
• 2. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 3. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 4. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 5. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Phenylmethylamines
• Solvents and Organic Chemicals Organic Compounds Heterocyclic Compounds

Professional Introduction to 1-benzylpyrrolidin-3-one (CAS No. 775-16-6)

1-benzylpyrrolidin-3-one, identified by the Chemical Abstracts Service registry number CAS No. 775-16-6, is a heterocyclic organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the pyrrolidinone class, characterized by a six-membered ring containing nitrogen and an oxygen atom in adjacent positions. The presence of a benzyl substituent at the 1-position and a carbonyl group at the 3-position imparts unique electronic and steric properties, making it a versatile scaffold for drug discovery and molecular design.

The structural motif of 1-benzylpyrrolidin-3-one has been extensively explored for its potential pharmacological activities. Its framework is conducive to interactions with biological targets, including enzymes and receptors, which are pivotal in modulating various physiological pathways. Recent studies have highlighted its role as a key intermediate in the synthesis of bioactive molecules, particularly in the development of small-molecule inhibitors targeting neurological and inflammatory disorders.

In the realm of medicinal chemistry, 1-benzylpyrrolidin-3-one has been utilized as a precursor in the synthesis of novel therapeutic agents. For instance, derivatives of this compound have shown promise in preclinical trials as potential treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's. The benzyl group enhances lipophilicity, facilitating better membrane permeability, while the pyrrolidinone core provides a rigid scaffold that can be modified to optimize binding affinity and selectivity.

One of the most compelling aspects of 1-benzylpyrrolidin-3-one is its adaptability in medicinal chemistry libraries. Researchers have leveraged its structure to develop compounds with enhanced pharmacokinetic profiles, including improved solubility and reduced toxicity. The introduction of various functional groups at different positions on the pyrrolidinone ring has led to the discovery of molecules with potent anti-inflammatory, analgesic, and even anticancer properties. These findings underscore the compound's significance as a building block in modern drug design.

The synthesis of 1-benzylpyrrolidin-3-one typically involves multi-step organic reactions, often starting from readily available precursors such as benzaldehyde and pyrrole derivatives. Advanced synthetic methodologies, including catalytic hydrogenation and palladium-catalyzed cross-coupling reactions, have been employed to achieve high yields and purity. These techniques not only streamline the production process but also allow for greater flexibility in modifying the compound's structure for targeted applications.

Recent advancements in computational chemistry have further accelerated the discovery process involving 1-benzylpyrrolidin-3-one. Molecular modeling studies have provided insights into how structural modifications influence binding interactions with biological targets. These simulations have guided experimental efforts, enabling researchers to design more effective derivatives with minimal trial-and-error experimentation. Such integrative approaches highlight the synergy between experimental synthesis and computational analysis in optimizing drug candidates.

The pharmacological profile of 1-benzylpyrrolidin-3-one has been scrutinized through both in vitro and in vivo studies. In cell-based assays, derivatives of this compound have demonstrated inhibitory effects on key enzymes implicated in disease pathogenesis. For example, certain analogs have exhibited potent activity against acetylcholinesterase, a target enzyme relevant to cognitive disorders. Similarly, animal models have shown promising results regarding anti-inflammatory and analgesic effects, reinforcing its therapeutic potential.

From a regulatory perspective, 1-benzylpyrrolidin-3-one (CAS No. 775-16-6) is classified as a chemical intermediate rather than an end-product pharmaceutical agent. This classification ensures that its production and handling adhere to stringent quality control measures without necessitating specialized regulatory approvals for direct therapeutic use. However, researchers must navigate safety protocols when working with this compound due to its reactivity and potential health hazards associated with organic solvents used in its synthesis.

The future directions for research on 1-benzylpyrrolidin-3-one are multifaceted. Ongoing studies aim to expand its utility beyond neurological disorders into other therapeutic areas such as oncology and metabolic diseases. Innovations in synthetic chemistry may lead to more efficient routes for producing complex derivatives, while advancements in drug delivery systems could enhance their bioavailability and efficacy. Collaborative efforts between academia and industry are expected to drive these developments further.

In conclusion,1-benzylpyrrolidin-3-one represents a valuable asset in pharmaceutical research due to its structural versatility and demonstrated biological activity. Its role as a scaffold for drug discovery continues to evolve with emerging scientific insights and technological innovations. As our understanding of molecular interactions deepens,1-benzylpyrrolidin-3-one will undoubtedly remain at the forefront of medicinal chemistry endeavors aimed at addressing unmet medical needs.

• 40114-49-6(1-benzylpiperidin-3-one)
• 16635-00-0(4-(Benzyl(methyl)amino)butan-2-one)
• 1012-01-7(1-Benzylpyrrolidin-3-one hydrochloride)
• 146407-32-1(1-Benzyl-azepan-3-one)
• 50866-56-3(1-Benzylpiperidine-3,5-dione)
• 69079-25-0(1-benzyl-4-methylpyrrolidin-3-one)
• 69079-26-1(1-Benzyl-2-methyl-3-pyrrolidone)
• 26734-07-6(2-Butanone,4-[bis(phenylmethyl)amino]-)
• 23770-07-2(1-Benzyl-5-methylpyrrolidin-3-one)
• 23982-57-2(n-benzylmethylamino-acetone)